CEO Update - 18 December 2023

The Department of Health and Social Care has published details of the 2024 Voluntary Scheme for Branded Medicines Pricing, while the British Academy opens funding support for Horizon programme applications. We also have an exclusive interview with Larry the Downing Street Cat, shedding light on his surprising life as a scientist.
 

DH publishes 2024 voluntary scheme for branded medicines

The Department of Health and Social Care has published the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth. The final terms are very similar to the Heads of Agreement published last month. The first quarter of the 2024 Voluntary Scheme, the period from 1 January 2024 to 31 March 2024, will be a transitional period and, during this period, a fixed payment rate of 19.5% will apply to all Eligible Sales.
 

New Funding scheme to support applications to Horizon 

The British Academy has opened a new funding call, to support applications into the Horizon programme. The aim is to pump prime collaborations to support the effective uptake of the opportunities provided by the UK’s association to Horizon Europe, with awards of £10,000 available. Each project must be led by  named Principal Investigator, and proposals are welcome from research institutes and universities based in the UK, and proposals that involve working closely with UK SMEs are strongly encouraged. Access the full criteria for the scheme here.
 

Check out our JP Morgan UK action guide

Although I've decided to pass this time around on the JP Morgan week, I encourage you to check out my blog on how to make the most of your time in San Franciso from sun-up to sundown. Read the full blog

In a Christmas exclusive, Larry the Downing Street Cat opens up to Steve Bates about his passion for science! 

Larry.jpg

On a recent visit to No.10 I managed an exclusive scoop with Larry the Cat. Larry said: “I’ve decided to break my silence as it is Christmas. It’s not just Dick Whittington’s cat who can talk. The Queen Mum was probably right when she said never give interviews, never explain – but I’ll never get on Netflix The Crown with that strategy. 

  • “I want to come out and tell the world. I’m a proper scientist and life science entrepreneur as well as a mouser, but I’ve been trapped in this political pantomime for 12 long years.

  • “I didn’t want to go to Downing Street: my primary ambition was the National History Museum. So it was the honour of my life to have a tiny marsh-loving beetle from India named after me by the European Journal of Taxonomy last year.

  • “(Coleoptera: Limnichidae) Caccothryptus larryi was described from the Himalayan region. Fantastic.

  • “At last someone recognised my passion– and I think it must have been that Patrick Vallance fellow, now Chair there, who was around a lot during the lockdown/party season.

  • “The press focus on my rows with other cats like Palmerston and occasional street fights here but I’m a serious life science champion : what I’ve really been working on is making the UK a fantastic place for life sciences. 

  • “This hasn’t been easy with all the chopping and changing – first it was David Cameron, then Theresa May, then Boris Johnson, then Liz Truss and now Rishi Sunak. And the first one is now back again over the road at the Foreign Office!  

  • “But with each I’ve got them to listen – the 100,000 Genome project, championing type 1 diabetes wearables when meeting Donald Trump, backing the Vaccines Taskforce, underpinning the LIFTS scheme at the British Business Bank, and supporting £500 million investment in medicine manufacturing – and don’t get me started on R+D tax credits for SMEs. Not bad for a domestic tabby cat.

  • “If I get out of this place in 2024 I see my future at the intersection of drug discovery and AI – where the UK has unique advantages, and I reckon I’ll set up shop in the Crick to begin with –I’m looking forward to bringing pioneering species diversity to the Institute."

On that inspirational note, I'll be taking a break from the blog over the festive break but will be back with a fresh take on 2024 in January.  I wish you all a restful Christmas and New Year.

All the best

Steve  

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

RSSL announces new Biotech Innovation Hub

RSSL, a leading pharmaceutical contract research organisation, has today announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products.

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

More within